Ireland
--:--IST
Latest
Clinical Trials in France / NCT06318780
Recruiting Not applicable

Concordance of Three Imaging Methods by Dynamic CT, Contrast Ultrasound and CT Angiography in the Characterization of Endoleaks in Patients With an Aortic Endoprosthesis

NCT06318780 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2024-02-28
Last updated
2025-05-25

Condition(s) studied

Aortic Diseases

Investigational drug(s) / intervention(s)

three-phase CT angiographyCEUS ultrasound

three-phase CT angiography: three-phase CT angiography

CEUS ultrasound: CEUS ultrasound

Study summary

Among patients who have undergone EVAR, there is a significant risk of 20-50% endoleak. These endoleaks often require secondary interventions to reduce the risk of expansion or rupture. Currently, three-phase CT angiography and CEUS ultrasound are recommended in the post-operative monitoring of EVAR but these remain limited in characterizing the type and source of endoleak. In this study the investigators will study the interest of d-CTA for a better detection and characterization of endoleaks.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients 18 years of age and older, * Patients who have received EVAR , * Detection of endoleak and/or with an aneurysmal sac enlargement greater than or equal to 5 mm over 6 months. Exclusion Criteria: * Minor patients, * absence of endoleak and growth of the aneurysmal sac (greater than or equal to 5 mm over 6 months), * patient under guardianship, curators, safeguard of justice, * patient deprived of liberty, * pregnant woman * Patient who does not benefit from a social security scheme

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
CHU Amiens Picardie Amiens Picardie Recruiting

More Centre Hospitalier Universitaire, Amiens trials in France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06318780 on ClinicalTrials.gov ↗ ← All trials in France